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The effect of delayed sterilization on the production of intravenous fluids using 5% (w/v) dextrose 
solution was studied. The 5% (w/v) dextrose was prepared with distilled water. The solution was 
inoculated with a laboratory isolate of Escherichia coli and thereafter divided into two: Solutions A and 
B. Sample A was sterilized within 1 h of innoculation, while B was incubated at 37°C for 48 h and 
sterilized after. The microbial load was determined before sterilization. Both samples were then tested 
for pyrogenicity using rabbit test of pyrogen. The results revealed a significant (P < 0.05) increase in E. 
coli  count in solution B from 8 ± 2 to 99 ± 5 cfu/ml after 48 h. Sample A became pyrogen-free after 
sterilization (sum of response (SR) of 3 rabbits, 0.75°C), while sample B contained 40 EU/ml (limit: ≤ 0.5 
EU/ml for large volume parenteral). A 10 times dilution of sample B with pyrogen-free 0.9% w/v sodium 
chloride produced a response of 2.80°C and SR of 3 rabbits (failed limit ≥ 2.65°C). From this study, a 
delay of up to 48 h before sterilizing solutions intended for parenteral use could produce high 
pyrogenicity. 
 





Intravenuous fluids are medications usually in volumes 
greater than 100 ml and are called large volume paren-
terals. The fluids which are administered through the 
veins must be sterile, particle and pyrogen-free, as well 
as must carry labels containing the constitutents for normal 
fluid  as per the label claims (British Pharmacopoeia, 
2002). 
Large volume parenterals are occassionally found con-
taminated with fungi, pathogenic bacteria and pyrogens 
(which are bacterial endotoxin) (Atata et al., 2007). 
Systemic injection of these pyrogens causes a cascade 
of reactions leading to the release of cytokines by macro-
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elevated body temperature and other adverse reactions 
characteristic of  sepsis  such  as  systemic  inflammatory 
response syndrome and infection (Bone et al., 1992). 
Exposure to pyrogens have been reported to have 
adverse effect such as hypotension, decreased cardiac 
output, increased pulmonary arterial pressure and vascular 
permeability in the lungs. Others include disseminated 
intravascular coagulation, activation and sequential 
damage to the heart, liver and lungs known as “Multiple 
Organ Failure Syndrome” (Charles, 2000). Therefore, 
there is the need to continue to make intravenous fluid 
that are free of pyrogens. Manufacturers of intravenous 
fluids are sometimes sanctioned for violation of current 
Good Manufacturing Practices (GMP) especially when 
cases of contamination of intravenous fluids are 
established. Contamination can result from poor and 
unhygienic handling during production (Hippenmier, 
1978) or in transit as well as during storage. 
The possible causes for the high pyrogen content of 
some infusions found in the Nigerian market had been 
attributed to non-compliance with GMP by the National 






(NAFDAC). However, there is need to investigate specific 
factor likely to account for such high pyrogen content of 
sterile preparations. In a country like Nigeria where supply 
of electricity  is  epileptic,  manufacturers  are  faced  with  
disruption in batch processing which leads to a possible 
delay in completion of a cycle of production. Manufac-
turers of intravenous fluids are not exempted from this.  
The objective of this study was to establish a link 
between the duration of production cycle and the pyrogen 
content of the resultant fluid. We also attempted to 
produce endotoxin from Escherichia coli using dextrose 
5% (w/v) as medium with a view to producing laboratory 
method for the preparation of bacterial endotoxin.  
The production of an infusion was simulated and diffe-
rent times of final sterilization of the solutions contami-
nated with E. coli were imposed. The resultant solutions 
were tested for initial microbial load and microbial load 
before sterilization and post sterilization. Pyrogen levels 
of the fluids obtained after sterilizations were tested using 
the official testing method for pyrogen according to The 
British Pharmacopoeia (2002). 
 
 




Pharmaceutical grade dextrose monohydrate, normally used for 
production of infusion was a product of Roquette Pharma, Cedex, 
Lestrem, France. E.coli was obtained from the Quality Control 
Laboratory of Biomedical Limited, Ilorin, Nigeria. Pyrogen-free, 
sterile, distilled water was used as solvent. Albino rabbits were 
obtained from the Animal House of  Biomedical Limited, Ilorin, 
Nigeria. Eosin methelene blue (EMB) agar, nutrient agar (NA) and 
sarboraud dextrose agar (SDA) were products of Sigma Aldrich Co 





The production of dextrose solution (5% w/v) infusion was simu-
lated using pyrogen-free distilled water. Actual infusion from 
pharmacies were not used because the condition of preparation 
could not be controlled for the purpose of this investigation.  
The solution was inoculated with laboratory isolates of E. coli. 
The microbial load of the solution was estimated by plating 1 ml of 
the sample on agar plates of SDA, EMB and nutrient agar (NA). 
Five replicates were made for each agar plate. EMB and NA plates 
were thereafter incubated  at 37°C for 24 h, while the SDA plates 
were incubated for 48 h. This represent the initial microbial load of 
all subsequent samples. The remaining solution was divided into 
two equal portions, A and B, and kept in sterile, de-pyrogenated (by 
heating in an oven at 250°C for 3 h) glass conical flasks (European 
Pharmacopoeia 2000). 
Soution A  which is the control was autoclaved at 118°C, 1.5 atm 
for 35 min within 1 h after the inoculation with E. coli; while solution 
B was incubated at 37°C for 48 h. At the end of 48 h, sample B was 
estimated for microbial load and treated as described earlier. The 
solution B was later autoclaved at 118°C, 1.5 atm. for 35 min. 
Solutions B were thereafter subjected to microbial load estimation 
to obtain the final microbial load before sterilization and was done 
again after sterilization. 
The sterilized solutiions A and B were subjected to pyrogen tests 
using the Rabbit test method (B. P., 2002).  Briefly,  sample  A  was  




injected into a set of three rabbits at a dose of 10 ml/kg, while 
sample B was diluted 1:9 with pyrogen-free, sterile 0.9% w/v  sodium 
chloride solution to reduce the expected endotoxin concentration by 
a  factor  of  10.  Another  dilution,  1:99  was  done  with  the  same 
diluent to give 100 percent diluted pyrogen content. Each of these 
solutions were injected into a set of 3 rabbits at a dose of 10 ml/kg.  
A control group was set up in parallel with the test groups by 
injecting sterile and pyrogen-free 0.9% w/v NaCl into another set of 
three rabbits as earlier described (B. P. 2002). The sum of 





The students t test was used. Results are expressed as mean ± 





The results in Table 1 shows that there was significant 
difference between initial  microbial load and microbial 
load 48 h after innoculation (p < 0.05). The final post-
sterilization microbial load was nil, meaning that the 
product could be sterile. The results on the pyrogen tests 
were interpreted according to the standard official method 
used. The pyrogen test result is as shown in Table 2. The 
sample B could not be injected directly in anticipation of a 
high pyrogen content but had to be diluted 1:9 and 1:99. 
The initial bacterial loads of A and B were actually the 
same. However, after 48 h, sample A had zero count, 
while B had an E.coli population of 99 ± 5 cfu/ml. The 
bacterial count of sample B was too numerous to count 
(TNTC) after 48 h, meaning that bacteria cells have 
greatly multiplied during the time lag. Fungal count 
increased from 1 ± 0.5 to 10 ± 1 cfu/ml (Table 1). These 
final counts were significantly different (P < 0.05). The 
pyrogen test results as shown in Table 2 indicated that 
sample A that was sterilized within 1 h after contami-
nation with E.coli became pyrogen free (sum of response 
of 3 rabbits, 0.75°C), while sample B sterilized in 48 h 
after contamination with E.coli failed pyrogen test when 






Manufacturers of infusions like any other manufacturer 
will not deliberately delay a production process such as 
sterilization, but local problem of electricity supply or any 
other technical hitch could cause a delay. Deliberate 
contamination cannot also happen. However, in the case 
of accidental contamination of the fluid, between mixing 
and sterilization, maybe due to human contact while 
filling, with a Gram negative pathogen such as E. coli could 
be dangerous.  
From our findings, a delay of up to 48 h before 
sterilization produced a sterile but pyrogenic solution. An 
average response of  0.93°C  was  observed  for  the  1:9   
 




Table 1.  Microbial load of E.coli contaminated dextrose 5% w/v solutions. 
 
Medium 
Initial count (cfu/ml) Count (after 48 hrs) Final count (after autoclaving) 














 Nil Nil 






 Nil Nil 
 
Values are expressed in mean ± SEM of 5 determinations. Values carrying diferent superscripts are significantly different at 




Table 2. Pyrogen Test Results of E.coli contaminated 5% Dextrose solutions. 
 
Sample 
Sum of response 
of 3 rabbits (°C) 
Pass limits (°C) Fail limit (°C) Comments 
Control (0.9%, w/v NaCl) 0.20 ≤1.15 ≥2.65 Pyrogen-free 
A 0.75 ≤1.15 ≥2.65 Pyrogen-free 
B (1:99 in 0.9%, w/v NaCl)  1.35 ≤1.15 ≥2.65 Slightly pyrogenic 
B  (1:9 in 0.9%, w/v NaCl) 2.80 ≤1.15 ≥2.65 Highly pyrogenic 
 
Results interpreted according to the British Pharmacopoeia, 2002. 
Sum of response of 3 rabbits measured as rise in body temperature over a period of 3 h.  




diluted sample. According to Dalmora et al. (2004), the 
equivalent amount of  endotoxin  in  the  solution  injected 
which is capable of eliciting such reaction is equivalent to 
4.0 EU/ml/kg body weight. The animals received 10 ml/kg 
solution that was diluted 10 times with pyrogen free 
physiological saline. Then the estimated content of the 
solution of pyrogen is therefore 40 EU/ml. This is highly 
toxic. The upper limit of bacterial endotoxin in large 
volume parenterals is 0.5 EU/ml. Sample A that was 
sterilized within 1 h after innoculation became pyrogen-
free after sterilization. This result indicates that delay in 
serilization further increases the risk of high pyrogen 
content of large volume parenterals (Table 2). Therefore, 
manufactures could be advised to make small batches 
that could be quickly filled and sterilized within reasonable 
time as prolonged time before sterilization will lead to 
proliferation of contaminating microbes and possibly high 
pyrogenicity. 
In this study, dextrose solution in water has proved to 
be a supporting medium for the growth of E. coli which 
has been the source of the pyrogen (Table 2) as a result 
of increased microbial load of gram negative pathogens 
when present as a contaminant (Table 1). 
Intravenuous fluids should be manufactured under 
controlled environments. The processes of manufacture 
should be carried out under various classes of air with 
respect to total viable count of organisms per cubic metre 
depending on the type of activity carried out in a compart-
ment. The critical processes should be carried out by 
highly trained personnel under asceptic conditions. Minimal 
human contact with the product during compounding, 
filling and stoppering and before sterilization is required. 
Terminal sterilization is required for parenterals which are 
not thermolabile, to remove the possible minimal con-
tamination of the bulk product during processing. Hence 
sterilization should be done within a very short period 





This research has conclusively investigated a possible 
explanation to the high pyrogenicity of infusions that are 
though sterile but pyrogenic. It underscores the contribution 
of lack of infrastuctures such as electricity to the proces-
sing of sensitive products such as infusions and its high 
risk to the Nigerian economy. 
In this research, endotoxin was successfully prepared 
using a simple culture of dextrose 5% (w/v) solution 
contaminated with E. coli. The potency of the endotoxin 
(pyrogen) is so high that the diluted samples still caused 
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